Business Description
Artiva Biotherapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US04317A1079
Total Employee Number:
106Description
Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials. The company pipeline includes AlloNK: is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of mAbs to drive B-cell. Others products includes: CAR-NK(AB201),CAR-NK(AB205).
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 8.46 | |||||
Equity-to-Asset | 0.83 | |||||
Debt-to-Equity | 0.12 | |||||
Debt-to-EBITDA | -0.12 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 17.1 | |||||
3-Year EPS without NRI Growth Rate | 19.2 | |||||
3-Year FCF Growth Rate | 19 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 55.89 | |||||
9-Day RSI | 57.4 | |||||
14-Day RSI | 55.73 | |||||
3-1 Month Momentum % | 1.93 | |||||
6-1 Month Momentum % | 62.41 | |||||
12-1 Month Momentum % | 332.08 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 8.16 | |||||
Quick Ratio | 8.16 | |||||
Cash Ratio | 7.98 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -1.8 | |||||
Shareholder Yield % | 0.69 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -67.51 | |||||
ROA % | -58.33 | |||||
ROIC % | -406.2 | |||||
3-Year ROIIC % | 140.43 | |||||
ROC (Joel Greenblatt) % | -496.48 | |||||
ROCE % | -66.88 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 2.71 | |||||
Price-to-Tangible-Book | 2.71 | |||||
EV-to-EBIT | -4.24 | |||||
EV-to-Forward-EBIT | -3.45 | |||||
EV-to-EBITDA | -4.37 | |||||
EV-to-FCF | -4.87 | |||||
| Price-to-Net-Current-Asset-Value | 3.36 | |||||
| Price-to-Net-Cash | 3.46 | |||||
Earnings Yield (Greenblatt) % | -23.58 | |||||
FCF Yield % | -17.16 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ARTV
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Ā
Total Annual Return % Ā
Artiva Biotherapeutics Inc Executives
DetailsGF Valueā¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -3.54 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 123.45 | ||
| 14-Day RSI | 55.73 | ||
| 14-Day ATR ($) | 0.888494 | ||
| 20-Day SMA ($) | 8.8015 | ||
| 12-1 Month Momentum % | 332.08 | ||
| 52-Week Range ($) | 1.55 - 14.53 | ||
| Shares Outstanding (Mil) | 48.59 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Artiva Biotherapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Artiva Biotherapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-12 | In 131 days | ||
| Second quarter earnings results for 2026 | 2026-08-06 | In 33 days | ||
| General meeting for 2026 | 2026-07-22 | In 18 days | ||
| H.C. Wainwright 4th Annual Cell Therapy | 2026-06-30 15:30 | 9.58 (+1.27%) | ||
| Artiva Biotherapeutics Post-EULAR Virtual Webcast | 2026-06-08 08:15 | 6.85 (-10.16%) | ||
| Guidance call for 2026 | 2026-06-04 09:20 | 6.97 (+0.29%) | ||
| First quarter earnings results for 2026 | 2026-05-08 | 12.52 (+1.46%) | ||
| 25th Annual Needham Virtual Healthcare Conference | 2026-04-15 14:15 | 7.49 (+3.31%) | ||
| Annual report for 2025 | 2026-03-10 | 5.71 (+1.38%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-10 | 5.71 (+1.38%) |
Show
Entries
Artiva Biotherapeutics Inc Frequently Asked Questions
What is Artiva Biotherapeutics Inc(ARTV)'s stock price today?
The current price of ARTV is $9.62. The 52 week high of ARTV is $14.53 and 52 week low is $1.55.
When is next earnings date of Artiva Biotherapeutics Inc(ARTV)?
The next earnings date of Artiva Biotherapeutics Inc(ARTV) is 2026-08-06 Est..
Does Artiva Biotherapeutics Inc(ARTV) pay dividends? If so, how much?
Artiva Biotherapeutics Inc(ARTV) does not pay dividend.
Guru Commentaries on NAS:ARTV
No articles.
Press Release
| Subject | Date | ||
|---|---|---|---|
| The $13 Million Company Teaching the Immune System to Hunt Cancer | 2026-05-29 |
Articles on Artiva Biotherapeutics Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers